Raymond C. Stevens, a director at Danaher Corp, has reported an acquisition of 152.741 phantom shares in the company. This transaction, which occurred on October 30, 2026, brings his total holdings to 7,580.576 shares. The acquisition is significant as it highlights the ongoing trends in executive compensation within the industrial instruments sector.
Danaher Corp, known for its work in industrial instruments for measurement, display, and control, has been recognized for its innovative approaches to executive compensation. Stevens' transaction reflects the company's commitment to aligning the interests of its directors with those of its shareholders.
According to the SEC filing, the phantom shares were acquired under the Non-Employee Directors Deferred Compensation Plan. This plan allows directors to defer their cash fees, which are then converted into notional shares of Danaher common stock based on the company's stock price at the time of the transaction. The price for the shares acquired by Stevens was reported at $232.23 per share.
The filing indicates that Stevens is fully vested in all amounts deferred under the plan, which further solidifies his commitment to Danaher's future performance. The nature of these phantom shares means that they will convert into actual shares of Danaher common stock on a one-for-one basis upon distribution.
This acquisition may affect investor perceptions regarding Danaher's governance and executive compensation practices, particularly as the company continues to navigate the competitive landscape of industrial applications and services. The filing does not specify what actions, if any, will follow this acquisition.
Read Next
Hampton Financial Corp Raises Governance Concerns Over Icon Energy
HCA Healthcare Executive Reports Multiple Stock Transactions
LENZ Therapeutics updates beneficial ownership in SEC filing
LOR Inc. Acquires Over 1.4 Million Shares of Rollins Inc.
Brian Magnusson Reports New Stock Transactions at Lindsay Corp
Klein Lawrence Otto Acquires 25,000 Shares in Oruka Therapeutics







